CTLA4 and cancer: In the past decade, the use of checkpoint inhibitors (CDK inhibitors, PD-[L]1 inhibitors, and CTLA4 inhibitors) has increased in cancer treatment and they have been proven to be effective for improving patients’ survival in a wide range of malignant diseases [9, 12].